文献速递认知障碍与痴呆

多模态核心1阿尔茨海默病生物标志物与认知的纵向关联

Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease.
PubMed 文献 · Neurology · 2025-10-17

该前瞻性观察研究纳入350名认知正常但AD痴呆风险增加的个体,随访3年,评估血浆p-tau217、脑脊液p-tau181/Aβ42及Aβ PET与mPACC评分的纵向关联。结果显示三种标志物升高均与mPACC下降相关,且在Aβ阴性阶段亦存在关联。

要点

  • 血浆p-tau217升高与认知下降显著相关,Aβ阴性组亦相关。
  • 脑脊液p-tau181/Aβ42比值升高与mPACC下降相关。
  • Aβ PET负荷增加与特定脑区认知下降相关,不同Aβ状态区域不同。

核心结论

  • 多模态核心1 AD生物标志物与认知功能在3年内存在显著纵向关联。
  • Aβ阴性阶段也观察到血浆p-tau217与认知下降的关联。

研究设计与样本

  • 前瞻性观察研究,纳入350名认知正常个体,来自西班牙巴塞罗那Alzheimer's and Families+队列。
  • 基线有脑脊液生物标志物测量,纵向神经心理评估2个时间点,随访3年。

主要发现

  • 全样本中,血浆p-tau217升高(βSTD=-0.124,95%CI -0.172至-0.076,p<0.001)与mPACC下降相关。
  • 全样本中,脑脊液p-tau181/Aβ42比值升高(βSTD=-0.059,95%CI -0.100至-0.019,p=0.005)与mPACC下降相关。
  • 全样本中,前额叶、扣带回、楔前叶和前颞区Aβ PET负荷增加与mPACC下降相关。
  • Aβ阳性组(35%)中,血浆p-tau217升高(βSTD=-0.121,95%CI -0.194至-0.049,p<0.001)和前颞区Aβ PET负荷增加与mPACC下降相关。
  • Aβ阴性组(65%)中,血浆p-tau217升高(βSTD=-0.084,95%CI -0.157至-0.011,p=0.024)和额顶区Aβ PET负荷增加与mPACC下降相关。

临床怎么用

  • 血浆p-tau217可用于追踪认知正常个体的细微认知下降。
  • Aβ PET有助于识别与认知下降相关的脆弱脑区。
  • 多模态标志物可互补用于识别和监测AD高风险认知正常个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Addressing the association between early-changing Alzheimer disease (AD) biomarkers and cognition is essential for characterizing preclinical AD. However, few studies have explored this relationship longitudinally, especially across multiple biomarker modalities. The aim of this study was to evaluate longitudinal associations of multimodal core 1 AD biomarkers with cognition in a cognitively unimpaired (CU) population at increased risk of AD dementia. METHODS: This prospective observational study included CU individuals from the Alzheimer's and Families+ cohort, based in Barcelona, Spain. Individuals had available baseline CSF biomarker measurements (normal or AD continuum profiles) and longitudinal neuropsychological assessments (2 time points, 3-year follow-up). The primary study outcome was the modified Preclinical Alzheimer's Cognitive Composite (mPACC) score. Study measurements included plasma phosphorylated tau (p-tau) 217, CSF p-tau181/β-amyloid (Aβ) 42, and Aβ PET ([¹⁸F]flutemetamol). Mixed-effects models were used to evaluate the longitudinal associations between fluid biomarkers and mPACC score; voxel-wise models were used to evaluate the longitudinal association between neuroimaging and mPACC score. Sensitivity analyses evaluated these associations stratifying by Aβ status. RESULTS: In total, 350 individuals were included (mean age: 61 years; 60% female; mean education: 14 years). In the full sample, increases in plasma p-tau217 concentration (βSTD = -0.124, 95% CI -0.172 to -0.076; p < 0.001), CSF p-tau181/Aβ42 ratio (βSTD = -0.059, 95% CI -0.100 to -0.019; p = 0.005), and Aβ PET load in the prefrontal cortex, cingulate cortex, precuneus, and anterior temporal regions were associated with mPACC decline. In the Aβ-positive group (35%), increases in plasma p-tau217 concentration (βSTD = -0.121, 95% CI -0.194 to -0.049; p < 0.001) and Aβ PET load in anterior temporal regions were associated with mPACC decline. In the Aβ-negative group (65%), increases in plasma p-tau217 concentration (βSTD = -0.084, 95% CI -0.157 to -0.011; p = 0.024) and Aβ PET load in frontoparietal regions were associated with mPACC decline. DISCUSSION: This study demonstrated significant longitudinal associations between multimodal core 1 AD biomarkers and cognitive function over 3 years in CU individuals, including those at the Aβ-negative stage. Distinct biomarker modalities provided complementary insights, emphasizing the potential of blood-based biomarkers for tracking subtle cognitive decline and neuroimaging for delineating vulnerable brain regions in aging and preclinical AD. These findings are crucial for identifying and monitoring high-risk CU individuals, further informing preventive intervention strategies for AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. López-Martos D, Suárez-Calvet M, Milà-Alomà M, et al. Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease. Neurology. 2025. PMID: 41105892. doi:10.1212/WNL.0000000000214308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。